All In MedTech

Device Trial Radar · NCT04204278

MONOVISC for Ankle Joint Pain Relief Due to Osteoarthritis

A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Ankle Joint

Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Dec 11, 2019

Primary completion

Feb 26, 2021

Study completion Mar 30, 2021

Sponsor

Lead sponsor
Anika Therapeutics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 18, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to demonstrate the clinical improvement and safety in patients treated with MONOVISC for ankle osteoarthritis. Specifically, this study will provide confirmation to the effectiveness and safety of MONOVISC at relieving ankle joint pain to 6 months post-treatment.

Conditions

  • Osteoarthritis Ankle

Interventions

  • MonoviscDevice

    A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numerical Rating Scale (NRS) Pain on WalkingTime frame: Baseline to 6 Months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Krajská zdravotní, a.s.

    Ústí nad Labem, Czechia

  • Nzoz Medi-Spatz

    Gliwice, Poland

  • SPORTO

    Lodz, Poland

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.